Gilead agrees to buy HongShan-backed developer’s HCXT-2001 program for USD 1.28 billion upfront
GILD•Gilead agreed on October 22, 2026, to acquire 瀚辰星泰’s Phase I oral IL-23R program for USD 1.28 billion upfront.
1. Program acquisition
Gilead agreed to acquire 瀚辰星泰’s Phase I oral IL-23R program for USD 1.28 billion upfront.
